Effect of renin-angiotensin system inhibitors on survival in glioma patients: A systematic review and meta-analysis.

Eur J PharmacolAug 20, 2026 (epub)
Clinical ResearchOncology (Medical)

Junyao He, Xue Sun, Yimin Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of renin-angiotensin system inhibitors (RASIs) on survival in glioma patients, analyzing data from seven studies involving 2660 patients. The overall survival (OS) did not significantly differ between RASIs-treated and non-treated patients (HR=0.89). However, in recurrent glioblastoma, RASIs were associated with significantly longer OS (HR=0.70).

Key findings

  • No significant difference in overall survival (OS) between RASIs-treated and non-treated glioma patients (HR=0.89).
  • In recurrent glioblastoma, RASIs treatment was associated with significantly longer OS (HR=0.70).
  • Combination of RASIs with bevacizumab significantly improved OS compared to bevacizumab monotherapy (HR=0.73).

Why it matters

Understanding the role of RASIs in glioma treatment could inform clinical decisions, particularly in recurrent glioblastoma, where survival outcomes may be improved with this therapy.

Source

PubMed · PMID 42624453

Published in Eur J Pharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.